• LAST PRICE
    1.8000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.7000/ 3
  • Ask / Lots
    1.9000/ 5
  • Open / Previous Close
    0.0000 / 1.8000
  • Day Range
    ---
  • 52 Week Range
    Low 0.8464
    High 3.6500
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 1.8
TimeVolumePIRS
09:32 ET49771.8
09:39 ET12001.79
09:42 ET7981.785
09:48 ET53991.8
09:50 ET26001.793
09:51 ET4001.785
09:53 ET5001.785
09:55 ET3001.785
10:00 ET1001.78
10:02 ET5001.78
10:09 ET5001.77
10:11 ET19001.75
10:27 ET48421.74
10:33 ET1001.735
10:36 ET5001.735
10:49 ET10001.7392
10:51 ET3001.735
10:54 ET18101.74
10:58 ET24901.7399
11:00 ET4001.74
11:05 ET10001.7375
11:14 ET19051.7393
11:16 ET1001.735
11:20 ET4001.735
11:32 ET2001.7391
11:57 ET3001.74
11:59 ET2001.735
12:01 ET5001.735
12:03 ET8001.735
12:06 ET3001.74
12:08 ET1001.73
12:10 ET2001.735
12:12 ET3001.735
12:14 ET3001.735
12:15 ET1001.73
12:17 ET3001.73
12:19 ET7001.74
12:26 ET3001.73
12:28 ET4001.72
12:32 ET1001.72
12:33 ET4001.73
12:37 ET56391.75
12:44 ET110001.765
12:46 ET2001.765
12:48 ET4001.77
12:53 ET15951.78
12:57 ET1001.79
01:00 ET1001.7907
01:02 ET2001.795
01:09 ET71001.795
01:13 ET1001.79
01:15 ET6001.795
01:18 ET10001.795
01:29 ET3001.795
01:31 ET1001.79
01:33 ET2001.795
01:36 ET4001.795
01:38 ET8001.78
01:40 ET2001.785
01:42 ET1001.78
01:44 ET4001.78
01:45 ET4521.78
01:47 ET5001.785
01:49 ET101481.775
01:51 ET1001.77
01:54 ET1001.775
01:58 ET23001.77
02:00 ET2001.77
02:02 ET2001.775
02:03 ET1001.77
02:05 ET4001.77
02:07 ET5001.78
02:12 ET1001.775
02:18 ET9001.775
02:20 ET21001.77
02:21 ET2001.77
02:27 ET2001.77
02:30 ET1001.77
02:32 ET2001.77
02:34 ET1001.77
02:36 ET8001.77
02:38 ET23771.77
02:39 ET1001.77
02:41 ET5001.775
02:45 ET1001.77
02:48 ET4001.77
02:50 ET2001.77
02:52 ET1001.77
02:54 ET5001.77
02:56 ET2001.77
02:57 ET1001.77
02:59 ET2001.77
03:01 ET51351.785
03:03 ET1001.785
03:10 ET33981.785
03:14 ET3001.785
03:15 ET1001.7825
03:17 ET3001.78
03:19 ET2001.78
03:21 ET1001.78
03:24 ET3001.78
03:26 ET15001.78
03:28 ET2001.78
03:30 ET2001.78
03:32 ET4001.78
03:33 ET1001.78
03:35 ET71781.78
03:39 ET1001.78
03:42 ET58001.785
03:44 ET20001.785
03:46 ET127401.79
03:48 ET10001.7999
03:50 ET62011.805
03:51 ET32001.8089
03:53 ET5001.805
03:55 ET36001.8
03:57 ET72341.8
04:00 ET96821.8
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPIRS
Pieris Pharmaceuticals Inc
133.9M
-3.8x
---
United StatesIKNA
Ikena Oncology Inc
138.5M
-2.7x
---
United StatesSLGL
Sol Gel Technologies Ltd
122.0M
29.1x
---
United StatesSESN
Sesen Bio Inc
121.7M
-35.5x
---
United StatesMDWD
Mediwound Ltd
126.6M
-3.7x
---
United StatesCELU
Celularity Inc
129.1M
-5.3x
---
As of 2023-02-08

Company Information

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline includes an inhaled IL-4Rα antagonist Anticalin protein to treat asthma, an immuno-oncology (IO), bispecific targeting HER2 and 4-1BB, and an IO bispecific targeting PD-L1 and 4-1BB. Its lead respiratory Anticalin-based drug candidate, PRS-060/AZD1402, which is antagonizes IL-4R alpha, thereby inhibiting by IL-4 and IL-13, two cytokines, which are small proteins mediating signaling between cells within the human body, known to be mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. The lead IO Anticalin-based drug candidate in its pipeline, cinrebafusp alfa, which is designed to target the immune receptor 4-1BB and the tumor target HER2. Cinrebafusp alfa is a genetic fusion of a variant of an HER2-targeting antibody with an Anticalin protein.

Contact Information

Headquarters
225 Franklin Street, 26Th FloorBOSTON, MA, United States 02110
Phone
857-246-8998
Fax
---

Executives

Independent Director
James Geraghty
President, Chief Executive Officer, Director
Stephen Yoder
Chief Financial Officer, Senior Vice President
Thomas Bures
Senior Vice President, Chief Scientific Officer
Hitto Kaufmann
Senior Vice President, Chief Business Officer, General Counsel, Company Secretary
Ahmed Mousa

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$133.9M
Revenue (TTM)
$28.5M
Shares Outstanding
74.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.18
EPS
$-0.47
Book Value
$0.70
P/E Ratio
-3.8x
Price/Sales (TTM)
4.7
Price/Cash Flow (TTM)
---
Operating Margin
-130.10%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.